Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma

Clinical Trial ID NCT02733809

PubWeight™ 0.00^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02733809

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.	Cancer Res	2004	21.36
2	Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?	Hepatology	2008	8.24
3	Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.	J Clin Oncol	2006	6.95
4	Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.	Cancer Res	2006	6.66
5	Randomized controlled trial of screening for hepatocellular carcinoma.	J Cancer Res Clin Oncol	2004	5.29
6	Resection and liver transplantation for hepatocellular carcinoma.	Semin Liver Dis	2005	4.51
7	Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance.	Gastroenterology	2004	2.91
8	Major achievements in hepatocellular carcinoma.	Lancet	2009	2.10
9	Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.	Methods Enzymol	2006	1.95
10	Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma.	N Engl J Med	2009	1.42
11	Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy.	Ann Surg Oncol	2008	1.33
12	Review article: Overview of medical treatments in unresectable hepatocellular carcinoma--an impossible meta-analysis?	Aliment Pharmacol Ther	1998	1.21
13	Sorafenib: in advanced renal cancer.	Drugs	2007	0.82